Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
Drug Nomenclature01:17

Drug Nomenclature

During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that the same...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Social Medicine Approaches to Community-Integrated Diabetes Care: A Narrative Review of Clinic-Based Triaging and Closed-Loop Referral Interventions.

Journal of general internal medicine·2026
Same author

Loss of productivity among commercially insured patients with pulmonary arterial hypertension in the United States.

Journal of medical economics·2026
Same author

Health Care Utilization and Cancer Screening Among Patients with Neurodivergence in a Safety-Net Adult Primary Care Clinic.

Journal of general internal medicine·2026
Same author

Liver Fat and Iron Quantification With Spectral Localizer Radiographs From Photon-counting Detector CT.

Investigative radiology·2025
Same author

The Impact of Parkinson's Disease Psychosis on Caregiver Burden: A Systematic Literature Review.

Neuroepidemiology·2025
Same author

A Dangerous Retreat: Defunding AHRQ and the Threat to Diagnostic Safety.

Journal of general internal medicine·2025
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
Same journal

Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism.

The Annals of pharmacotherapy·2026
Same journal

A Comparison of Phenobarbital Dosing Strategies for the Treatment of Alcohol Withdrawal Syndrome.

The Annals of pharmacotherapy·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Physician perceptions about generic drugs.

William H Shrank1, Joshua N Liberman, Michael A Fischer

  • 1Brigham and Women's Hospital and Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School, Boston, MA, USA. wshrank@partners.org

The Annals of Pharmacotherapy
|January 6, 2011
PubMed
Summary
This summary is machine-generated.

Physician perceptions of generic medications reveal barriers to cost-effective use. Older physicians show more negative views on generic efficacy and quality, impacting prescribing habits.

Related Experiment Videos

Last Updated: Jun 5, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Area of Science:

  • Health Services Research
  • Pharmacoeconomics
  • Medical Education

Background:

  • Constrained healthcare resources necessitate understanding barriers to cost-effective medication use.
  • Physician perceptions significantly influence medication choices and adherence.

Purpose of the Study:

  • To investigate physician perceptions regarding generic medications.
  • To identify factors influencing these perceptions and their impact on generic prescribing.

Main Methods:

  • Survey of physicians using 5-point Likert scales to assess perceptions.
  • Analysis of data on cost-related nonadherence, efficacy, quality, and preferences for generics.
  • Logistic regression to identify predictors of physician perceptions.

Main Results:

  • Over 23% of physicians held negative perceptions about generic drug efficacy, and nearly 50% about quality.
  • Physicians over 55 were significantly more likely to report negative perceptions and avoid generics for themselves/family.
  • Pharmaceutical representatives were the primary information source (75%) on generic market entry.

Conclusions:

  • A substantial proportion of physicians harbor negative perceptions about generic medications, posing a barrier to their optimal use.
  • Targeted educational initiatives for older physicians may be beneficial for payors and policymakers aiming to increase generic utilization.